Abstract
Chemical reactions that occur via the exchange of electrons are termed redox reactions. Normally the carbon atom changes its oxidation state in biochemical redox processes. As a general rule, derivatives with a significant number of directly bound hydrogen atoms are transformed into derivatives with a larger number of contacts to nitrogen, oxygen, and sulfur in oxidations. Because these bonds to the above-mentioned electronegative elements are usually associated with the introduction of polar functional groups, redox reactions exert a decisive influence on the physicochemical properties of the oxidized substances. For example, the water solubility is increased. This is of great importance for the elimination of xenobiotics. Cytochrome P450 enzymes, a large group of oxidizing enzymes, are involved in the corresponding metabolic transformations. On the other hand, reductions are of crucial importance for the organism too. In these reaction steps, reactive aldehydes or ketones are transformed into alcohols, which subsequently are more easily conjugated and eliminated (Sect. 8.1). Transition metals, which can adopt a variety of oxidation states, are predestined to serve as electron donors and acceptors in redox reactions. In biological systems, one transition metal, iron, is often used for this task. Once incorporated in a protoporphyrin ring scaffold, it exists in penta- or hexavalent coordination state and can take on oxidation states between +2 and +4. Moreover, it participates in complexes with sulfur. There it forms interesting multinuclear structures: the so-called iron–sulfur cluster. In addition to iron, copper also plays a role as a mediator of biochemical redox processes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
General Literature
Chan DCN, Anderson AC. Towards species-specific antifolates. Curr Med Chem. 2006;13:377–98.
Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B. 2010;86:484–93.
Flower RJ. The development of COX-2 inhibitors. Nat Rev Drug Discov. 2003;2:179–91.
Gangjee A, Jain HD. Antifolates – past, present and future. Curr Med Chem Anti-Cancer Agents. 2004;4:405–10.
Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev. 2007;39:87–144.
Lamb DC, Waterman MR, Kelly SL, Guengerich FP. Cytochromes P450 and drug discovery. Curr Opin Biotechnol. 2007;18:504–12.
Michaux C, Charlier C. Structural approaches for COX-2 inhibition. Mini Rev Med Chem. 2004;4:603–15.
Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75–86.
Oates P. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14–36.
Tobert JA. Lovastatin and beyond: the history of HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2:517–26.
Vagelos PR. Are prescription drug prices high? Science. 1991;252:1080–4.
Webster SP, Pallin TD. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents. Expert Opin Ther Patents. 2007;17:1407–22.
Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004;3:739–48.
Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4:825–33.
Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53:6811–24.
Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295–309.
Special Literature
Bertilsson L, Lou YQ, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of Debrisoquin and S-Mephenytoin. Clin Pharmacol Ther. 1992;51:388–97.
Cody V, Pace J, Chisum K, Rosowsky A. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(ω-Carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions. Proteins. 2006;65:959–69.
Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem. 2004;4:1733–44.
De Colibus L, Li M, et al. Three-dimensional structure of human monoamine oxidase (MAO A): relation to the Structure of rat MAO A and human MAO B. PNAS. 2005;102:12684–9.
Ekroos M, Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. PNAS. 2006;103:13682–7.
FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879–90.
Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J. Crystal structure of the catalytic ortion of human HMGCoA reductase: insights into regulation of activity and catalysis. EMBO J. 2000;19:819–30.
Rosowsky A, Forsch RA, Wright JE. Synthesis and in vivo antifolate activity of rotationally restricted aminopterin and methotrexate analogues. J Med Chem. 2004;47:6958–63.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Klebe, G. (2013). Oxidoreductase Inhibitors. In: Klebe, G. (eds) Drug Design. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17907-5_27
Download citation
DOI: https://doi.org/10.1007/978-3-642-17907-5_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17906-8
Online ISBN: 978-3-642-17907-5
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences